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Background: Despite widespread coverage of the emergence of artemisinin resistance, relatively little is known
about the parasite populations responsible. The use of PCR genotyping around the highly polymorphic Plasmodium
falciparum msp1, msp2 and glurp genes has become well established both to describe variability in alleles within a
population of parasites, as well as classify treatment outcome in cases of recurrent disease. The primary objective
was to assess the emergence of minority parasite clones during seven days of artesunate (AS) treatment in a
location with established artemisinin resistance. An additional objective was to investigate whether the classification
of clinical outcomes remained valid when additional genotyping was performed.
Methods: Blood for parasite genotyping was collected from 143 adult patients presenting with uncomplicated
falciparum malaria during a clinical trial of AS monotherapy in Western Cambodia. Nested allelic type-specific
amplification of the genes encoding the merozoite surface proteins 1 and 2 (msp1 and msp2) and the
glutamate-rich protein (glurp) was performed at baseline, daily during seven days of treatment, and again at failure.
Allelic variants were analysed with respect to the size of polymorphisms using Quantity One software to enable
identification of polyclonal infections.
Results: Considerable variation of msp2 alleles but well-conserved msp1 and glurp were identified. At baseline, 31%
of infections were polyclonal for one or more genes. Patients with recurrent malaria were significantly more likely
to have polyclonal infections than patients without recurrence (seven of nine versus 36 of 127, p = 0.004).
Emergence of minority alleles during treatment was detected in only one of twenty-three cases defined as being
artemisinin resistant. Moreover, daily genotyping did not alter the final outcome classification in any recurrent cases.
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Conclusions: The parasites responsible for artemisinin-resistant malaria in a clinical trial in Western Cambodia
comprise the dominant clones of acute malaria infections rather than minority clones emerging during treatment.
Additional genotyping during therapy was not beneficial. Disproportionately high rates of polyclonal infections in
cases of recurrence suggest complex infections lead to poor treatment outcomes. Current research objectives
should be broadened to include identification and follow-up of recurrent polyclonal infections so as to define their
role as potential agents of emerging resistance.
Keywords: Malaria, Plasmodium falciparum, Cambodia, Genotype, Artesunate, msp1, msp2, glurpBackground
With the emergence of artemisinin resistance in West-
ern Cambodia and along its international border with
Thailand as well as further afield in Vietnam and along
Thailand’s western border with Myanmar, there is a pub-
lic health mandate to characterize the parasite popula-
tions responsible for poor clinical outcomes, as well as
better understand the dynamics of how these parasite
clones co-exist [1-3]. Gene flow studies and complex
whole genome sequencing analyses offer highly sophisti-
cated approaches and have already been employed in
this region in an attempt to define the aetiology of the
emergence and spread of resistance [4,5]. However these
approaches are costly and require considerable expertise
both to analyse samples and interpret the data.
The use of polymerase chain reaction (PCR) genotyp-
ing around a limited number of polymorphic genes,
which are known to be highly variable in Plasmodium
falciparum parasites, has become well established both
to describe variability in alleles within a population of
parasites, as well as to distinguish recrudescence from
new infection in cases of recurrent disease [6-8]. This
technique is relatively cost-efficient and straightforward
to perform without requiring extensive sequencing and
bioinformatics capabilities. The technique provides a
basic description of parasite populations and diversity
within a patient cohort using these highly variable para-
site genes, as well as classification of recurrent malaria
episodes as recrudescent (true failures) or new infec-
tions. The most widely used PCR genotyping assay in-
volves nested allelic type-specific amplification of the
genes encoding the merozoite surface proteins 1 and 2
(msp1 and msp2) and the glutamate-rich protein (glurp)
[8,9]. This method is highly sensitive and allows for clas-
sification of allelic variants including minor variants in
mixed clonal infections [10]. The use of high-resolution
methods, such as repeated agarose gel electrophoresis
with computer image software, for determining DNA
band size has increased the ability to distinguish and
analyse PCR products that differ only slightly in size and
thus have improved the accuracy of this technique.
MSP1 block 2 allelic variants fall under three major
types - MAD20, K1 and RO33. The msp2 gene can besimilarly grouped into two allelic families, FC27 and
IC3D7 [11,12]. Only size variation, due to the different
number of repeats, has been observed within the glurp
gene [9].
The present analysis was conducted as part of a clin-
ical trial of artesunate (AS) monotherapy designed to
probe for and characterize clinical artemisinin resistance
in adult patients with uncomplicated P. falciparum mal-
aria. The trial was conducted in a rural district of West-
ern Cambodia, close to the international border with
Thailand and where reports of AS treatment failures had
already emerged [13]. The main objective of this study
was to describe changes in parasite genotype during
seven days of AS treatment in patients classified as arte-
misinin resistant and assess for emergence of novel (mi-
nority) parasite populations that were not detected at
baseline. Secondary objectives were: (1) to describe the
diversity of msp1, msp2 and glurp in this Cambodian
study population, and (2) to assess whether conventional
classification of recrudescence/re-infection based on
samples collected only at baseline and day of failure
(Df ) remained valid once interim sampling was per-
formed. There were two working hypotheses. Firstly,
that AS-resistant patients were infected with novel sub-
populations of relatively drug-resistant parasites not
identified at baseline; as the majority of more sensitive
parasites were killed, the resistant parasites would per-
sist and become detectable during a seven-day course
of AS therapy. Secondly, that new falciparum infections
during follow-up had persistence of these intrinsically
more resistant parasite subpopulations. Hence, these
cases should be reclassified as recrudescent, making the
true failure rate higher with longitudinal genotyping




Study setting and participants
The study was part of a randomized clinical trial con-
ducted during 2008-2009 at Tasanh Health Center lo-
cated in Battambang Province in Western Cambodia, a
region of low malaria transmission, with just one third
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episodes of malaria. Full details of the study are de-
scribed elsewhere [14]. Briefly, after giving informed
consent, screening procedures were conducted, and eli-
gible patients with uncomplicated P. falciparum malaria
were randomized to receive one of three AS monother-
apy regimens given as a single daily oral dose: 2, 4 or
6 mg/kg/day (n = 75, 40, and 28, respectively) for seven
days. Inclusion criteria were age 18 to 65 years, fever or
history of fever within 48 hours of presentation, mono-
infection with P. falciparum as determined on Giemsa-
stained thick and thin blood films by light microscopy,
and parasite density 1,000-200,000 asexual parasites/ml
blood. Exclusion criteria were signs and symptoms of se-
vere malaria and documented use of anti-malarial drugs
within the preceding 30 days. All patients remained on
the study ward for the first week until completion of AS
administration and returned for weekly outpatient re-
view until Day 42. Patient outcomes for the main treat-
ment study were classified according to clinical and
parasitological responses [15]. Primary analysis for this
molecular study was intent-to-treat so as to include add-
itional subjects who had given informed consent to par-
ticipate, including withdrawal and screening failure cases
where a baseline blood sample for molecular genotyping
had been collected. The study was approved by the
WRAIR IRB, World Health Organization Ethical Review
Committee (WHO ERC), and the Cambodian Ethics
Committee for Human Research (NECHR).
For the longitudinal genotyping analysis conducted over
the first seven days (Days 0 to 6), three subgroups of
patients were selected and defined as follows: (Group A)
“artemisinin sensitive” (rapid resolution of symptoms plus
asexual parasite clearance time <48 hours by microscopy
and remained cured to 42 days) (n = 18); (Group B) “slow
parasite clearance” (parasite clearance time >96 hours by
microscopy and remained cured of P. falciparum through-
out the follow up period (n = 14); (Group C) “Recurrence”
(re-appearance of asexual P. falciparum parasites, as deter-
mined by light microscopy, during follow up after initially
clearing parasitaemia, with or without clinical symptoms/
signs of malaria (n = 9). Groups B and C when combined
were termed “artemisinin resistant”. Group D constituted
the remaining patients not included in A, B or C. For the
purposes of the present analysis, enrolled patients devel-
oping Plasmodium vivax mono-infection during follow-
up and confirmed by vivax-specific PCR were considered
cured of P. falciparum infection.
Sample collection
Prior to initiation of AS therapy (Day 0), blood for para-
site density, species confirmation and genotyping was
collected into EDTA. Further samples were collected
daily on Days 1 to 6 and again on the day of treatmentfailure (Df) if malaria recurrence occurred. All samples
were transferred to cryovials, stored in liquid nitrogen at
the study site for transfer to Bangkok, and then kept fro-
zen at -80°C until used for DNA extraction.
Laboratory methods
Genotyping of Plasmodium falciparum
Genomic DNA was extracted from 200 μl whole blood
per patient using the Qiagen DNA extraction kit (QIA-
GEN, USA) according to manufacturer’s instructions. The
polymorphic regions of the merozoite surface proteins
msp1 (block 2), msp2 (block 3), and glurp (R2 repeat
region) were amplified by nested PCR. In the primary re-
action, the oligonucleotide primers corresponded to con-
served sequences within msp1 (block 2), msp2 (block 3)
and glurp, and in the nested reaction, separate primer
pairs targeted the respective allelic types of msp1 (K1,
MAD20, and RO33) and msp2 (FC27 and IC3D7) for
amplification [11]. For controls, genomic DNA from a
3D7 laboratory strain was isolated by standard techniques.
Positive and negative controls were systematically incor-
porated in each PCR run. The msp1, msp2 and glurp PCR
products were loaded on 2% agarose gels, stained with
ethidium bromide, separated by electrophoresis and visu-
alized under UV trans-illumination (VersaDoc®, BIORAD,
Hercules, USA). Samples from an individual patient were
run in adjacent lanes. If there was no amplification for any
allelic family, the PCR was repeated with three times the
quantity of template DNA. If no amplification was de-
tected after this second reaction, amplification was classi-
fied as unsuccessful. Analyses of number of genotypes and
size polymorphism were digitalized using Quantity One®
software (Bio-Rad Laboratories, Hercules, USA). A mini-
mum of ten base pairs size difference was required to de-
fine an additional genotype.
Determination of PCR-corrected response
Comparison of genotyping patterns of msp1, msp2 and
glurp at baseline and at Df was used to classify parasito-
logical outcomes for LTF cases. Genotyping was done
stepwise with an initial msp2 determination, followed by
msp1 genotyping of the paired blood samples found to
have at least one identical msp2 allele before and after
treatment. Based on analysis of the 3D7 strain, alleles
were considered the same if molecular weights were
within ten base pairs (bp) [2,6]. It was assumed that after
a patient was initially treated for malaria, a subsequent
malaria episode was caused by either parasite strains
present before treatment (e.g., recrudescence) or parasite
strains acquired after completion of treatment (e.g., new
infection). An outcome was defined as recrudescence if
a subsequent sample contained identical alleles or a sub-
set of the alleles present in the first sample [8]. If a sub-
sequent sample contained alleles present in the first
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recrudescent. An outcome was defined as a new infec-
tion if a subsequent sample contained only new alleles.
Allelic variants were analysed only with respect to the size
of polymorphisms given the high level of discrimination
afforded by the Quantity One® software computer analysis.
Statistical methods
Continuous data were expressed as medians with inter-
quartile ranges or, in the case of parasite counts, as geo-
metric means with 95% confidence intervals (95% CI).
Continuous data from patient groups were compared
using the non-parametric Kruskall-Wallis test. Numer-
ical data were expressed as proportions and compared
using Chi-square or Fisher’s exact tests as appropriate.
All statistical tests were performed at the 5% significance
level and corresponding 95% confidence intervals were
estimated. Statistical analyses were performed using
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) and
Stata version 11 (College Station, TX, USA).
Results
PCR genotyping was successful for one or more genes in
baseline samples from 143 patients who had undergone
screening procedures prior to study enrolment (msp1 125,
msp2 137 and glurp 143). Four patients were subsequently
determined not to meet all treatment study entry criteria,
but genotype samples from these cases were retained for
this molecular analysis. Some 139 patients were randomized
to one of three oral AS monotherapy regimens; three were
subsequently lost to follow-up while the remaining 136
were followed until a study endpoint was met. One case re-
presented with recurrence 56 days after enrolment into the
treatment study and was included in this analysis; another
developed neutropenia on D3 and was withdrawn from the
treatment study but retained for safety follow up and devel-
oped malaria recurrence at D42. Baseline characteristics
and clinical/parasitological outcomes for patients are given
in Table 1. Subjects termed artemisinin-resistant (Groups B
and C combined) had significantly higher presenting para-
sitaemia and slower parasite clearance rates and times than
those in Group A (artemisinin-sensitive) (p < 0.0001 for all
comparisons). Approximately one quarter of the study
population, including nearly half of the malaria recurrence
cases, had gametocytes documented by microscopy at some
point during the 42-day study follow-up period; however,
gametocytes were detected in only two cases at the same
time a PCR genotyping sample was collected: one in Group
A (at baseline) and one in Group C (at Df).
Population diversity of msp1, msp2 and glurp at baseline
Population diversity
There was more genotypic variation in msp2 (51 alleles)
than msp1 (24 alleles) and glurp (34 alleles) (Figure 1).The length variations of the msp1-amplified product
were approximately 100-330 bp for K1, 150-320 bp for
MAD20 and 220-230 bp for RO33. For msp2, the length
variations of the amplified product were approximately
170-820 bp for FC27 and 290-870 for IC3D7, while glurp
showed 660-1,090 bp of length variation.
Haplotypes
Some 13 distinct patterns of genotype (haplotypes) were
observed at baseline (Tables 2 and 3, Figure 2). Recurrent
cases were comprised of just three haplotypes: msp1-K1/
msp2-IC3D7, msp1-K1/msp2-FC27 and msp1-MAD20/
msp2-FC27; these three haplotypes were also prominent
in Groups A and B, and therefore probably not associated
with clinical phenotype. In contrast, haplotypes containing
msp2-RO33 were observed in some AS-sensitive cases
(5/18, 28%), but not in the AS-resistant subgroup.
Complexity of infection
Overall, 45/143 (31%) of the study population had evi-
dence of a polyclonal infection at baseline with two or
more msp1, msp2 or glurp alleles present (Tables 2 and 3).
Multiple alleles were detected in 17% (21/125) msp1,
26% (36/138) msp2 and 8% (12/143) glurp samples,
respectively. The maximum number of clones seen for a
single gene was six (one case with six clear bands of
msp2-FC27 in addition to two clones of msp1-K1); this
case remained cured at 42 days but had a prolonged
parasite clearance time of 102 hours. All other poly-
clonal infections had just two or three clones. In the
three subgroups of artemisinin sensitive, slow clearers
and recurrences, multiple P. falciparum alleles of msp-1,
msp-2 and glurp, were detected in 5/18, 3/14 and 7/9
patients (28, 21 and 79%, respectively) (Figure 3). Recur-
rence patients were significantly more likely to have
polyclonality of one or more alleles demonstrated at
baseline than patients without falciparum recurrence
(seven of nine versus 36 of 127, p = 0.004). Five of nine
cases were polyclonal at Df.
Parasite genotype during seven-day artesunate therapy
and at failure
Parasite genotype was evaluated daily on Days 0-6 of AS
therapy for individual recurrence cases (Figure 3). In all
participants, peripheral parasitaemia cleared by Day 4 of
AS therapy although genotyping PCR assay performed
retrospectively demonstrated the continued presence of
parasites through Day 6.
Detection of minority parasite populations during
treatment
Only one case of recurrence had a new allele (msp2-
3D7) observed on Days 3 and 5, when asexual parasit-
aemia was still positive by light microscopy; this could
Table 1 Baseline characteristics and clinical and parasitological outcomes in groups of patients with Plasmodium falciparum malaria followed with sequential
parasite genotyping during 7 days of artesunate monotherapy









Number of cases 18 14 9 23 102 143
Age (y), median (IQR) 25 (18-32) 25 (21-31) 22 (18-27) 23 (20-31) 25 (20-38) 25 (20-35)
Male:female, n (%) 16:2 (89:11) 13:1 (93:7) 6:3 (67:33) 19:4 (83:17) 77:25 (75:25) 112:31 (78:22)
Parasitaemia (/uL), geometric mean (95%CI) 6,698 (3,564-12,589) 51,944 (28,540-94,542) 22,209 (9,193-53,653) 37,251 (22,776-60,926) 11,527 (4,933-32,687) 14,207 (4,891-37,778)
Allocated daily AS monotherapy dose: 2 - 4 - 6 (mg/kg/day), n+ 10 - 5 - 3 3 - 8 - 3 4 - 2 - 3 7 - 10 - 6 58 - 25 - 19 71 - 40 - 28
Parasite clearance time by microscopy (h), median (IQR) 36 (30-42) 108 (102-108) 96 (84-96) 102 (96-108) 74 (66-84) 78 (60-90)
Parasite clearance rate* (/h), median (IQR) 0.086 (0.059-0.11) 0.036 (0.033-0.038) 0.035 (0.030-0.041) 0.036 (0.033-0.039) 0.040 (0.034-0.047) 0.040 (0.034-0.052)
Parasitological outcome at D42, n (%)
Cured 18 (100) 14 (100) 1 (11)^ 15 (65)^ 96 (96) 131 (92)
Recrudescence** 0 0 7 (67) 7 (30) 0 (0) 7 (5)
New Pf infection** 0 0 1 (11) 1 (4) 0 (0) 1(1)
No outcome recorded 0 0 0 0 4 (4)+ 4 (3)
Gametocytes by microscopy, n (%)
At baseline 1 (6) 1 (7) 1 (11) 2 (9) 16 (16) 19 (13)
During week 1 3 (17) 1 (7) 1 (11) 1 (4) 26 (25) 30 (21)
Any time D0-42 3 (17) 0 4 (44) 4 (17) 29 (28) 36 (26)
Key. * Calculated using slope of curve for log10-normalised parasite clearance as determined by light microscopy [14].
+ 4 screening failure cases received standard AS-MQ treatment and had baseline data recorded only.
** Outcome determined using genotyping based on msp1, msp2 and glurp fragment sizes on paired blood samples collected at baseline and Df.
^ Includes one case classified per protocol as cured on D42 but self-presented with recurrent malaria on D58 which was subsequently determined to be recrudescence by PCR genotyping.
h = hours; y = years.
















Figure 1 (See legend on next page.)
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Figure 1 Parasite genetic diversity detected by msp1, msp2 and glurp. Polymerase chain reaction (PCR) products were categorized into
molecular weight groups differing by 10 bp. (A) msp1. Orange bars represent K1; brown bars, MAD-20; and yellow bars, RO33 allelic families.
The 18 K1 alleles ranged in size from 100 to 330 bp; the 5 MAD-20 alleles; 150 to 320 bp; and the 1 RO33 alleles, 220-230 bp. (B) msp2. Red bars
represent FC27 and black bars represent IC3D7 allelic families. The 18 FC27 alleles ranged in size from 170 to 820 bp, and the 33 IC3D7 alleles
ranged in size from 290 to 870 bp. (C) glurp. The glurp alleles ranged in size from 660 to 1,090 bp. Dashed purple lines represent fragment size
thresholds for each gene [10].
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to AS treatment. However, this allele was not detected
again at Df. In the remaining eight recurrence cases,
while fewer of the alleles present at baseline were de-
tected as parasitaemia cleared, no new alleles emerged.
In the 14 patients with prolonged parasite clearance
but no recurrence of malaria (Group B) no minority al-
leles emerged during seven days of treatment.Table 2 Haplotypes of msp1 and msp2 seen in 143 cases of u
Type Haplotype pattern Polyclonal
for >1
allele
msp1 msp2 Fast clearers Slow cl
(n = 18) (n =
1 MAD20 IC3D7 No 1 -
Yes - -
2 MAD20 FC27 No - -
Yes - -
3 MAD20 IC3D7/FC27 No - -
Yes 1 -
4 MAD20/K1 IC3D7/FC27 No - -
Yes - 1
5 K1 IC3D7 No 3 4
Yes 3 -
6 K1 FC27 No 3 5
Yes - -
7 K1 IC3D7/FC27 No 1 1
Yes 1 2
8 K1 - No - -
Yes - -
9 RO33 IC3D7 No 2 -
Yes - -
10 RO33 FC27 No 2 -
Yes - -
11 RO33 IC3D7/FC27 No 1 -
Yes - -
12 - IC3D7 No - -
Yes - -
13 - FC27 No - 1
Yes - -Determination of parasitological outcome in recurrent
malaria (LTF) cases
Based on conventional genotyping methodology using
only baseline and Df samples, eight of nine (89%)
Plasmodium falciparum recurrences were determined to
be recrudescent and one of nine (11%) was a new infection.
Longitudinal genotyping on days 1-6 revealed that in six of
nine cases no new minority parasite populations werencomplicated P. falciparum malaria
Number of cases
earers Malaria recurrences Remaining cases Total population



























Table 3 Number of patients with msp1 or msp2 genes detected at baseline
Genotype Artemisinin sensitive Slow parasite clearers Recurrences Remaining cases Total population
n = 18 n = 14 n = 9 n = 102 n = 143
msp1
MAD20 2 (29) 1 (14) 0 4 (57) 7
K1 11 (9) 13 (11) 8 (7) 86 (73) 118
RO33 5 (72) 0 0 2 (29) 7
No msp1 detected 0 1 (8) 1 (8) 11 (85) 13
msp2
IC3D7 13 (14) 8 (8) 7 (7) 69 (71) 97
FC27 9 (15) 10 (17) 2 (3) 38 (65) 59
No msp2 detected 0 0 0 6 (100) 6
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tion of recrudescence, although not all alleles present at
baseline were detected at the time of recurrence. In one
case (participant 140) described above, minority alleles
were observed on Days 3 and 5 of AS treatment but not on
Df. and thus the classification remained as recrudescence.
One case (88) was also classified as recrudescent based on
the appearance of at least one allele present in the baseline
sample, as well as novel alleles at Df. Case 112 was classi-
fied as a new infection based on the appearance of novel al-
leles at the time of recurrence, none of which were
observed during the first week. Thus in all nine cases of
malaria recurrence, additional genotyping during AS treat-
ment on days 1-6 did not alter classification of the final
parasitological outcome.Figure 2 Pie charts showing genotype frequencies of msp1 and msp2
sensitive) (n = 14), slow parasite clearers (n = 18), recurrences (n = 9),
populations. Key: orange, brown, yellow =msp1; dark green = no msp1; blDiscussion
This study aimed to detect emerging drug-resistant mi-
nority parasite clones during slowly clearing malaria in-
fections that could account for cases of unrecognized
treatment failure in a setting of clinical AS resistance. In
fact, of the 23 cases in the artemisinin-resistant sub-
group in whom daily parasite genotyping was under-
taken for seven days, including nine cases with recurrent
disease, a minority clone was detected in only one;
moreover this clone was not present at Df, so did not ap-
pear to be associated with subsequent treatment failure.
Two of the 23 cases had novel alleles present at Df but
these had not been detected at all during AS therapy
despite the sensitivity of the molecular methods used. In
this Cambodian setting, where most enrolled patientsdetermined at baseline for fast parasite clearers (artemisinin
and for remaining (n = 102) and overall (n = 143) study
ack, red =msp2; lime green = no msp2.
A. Recrudescence cases  (n=8)
B. New infection  (n=1)
Figure 3 (See legend on next page.)
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Figure 3 Parasite genotype determined daily in individual patients with malaria recurrence (Group C). Allele typing displaying size
variation of 18 s alleles for msp1, msp2 and glurp in P. falciparum parasites isolated from nine patients showing the patterns of alleles present
during seven days of AS monotherapy and on the day of falciparum malaria recurrence. Key: Bp = base pairs; PCT100 = duration of parasite
clearance by microscopy; bands = separate clones for the same allele; dayR = day of malaria recurrence. Dashed lines represent asexual
parasitaemia determined by microscopy. (A) Recrudescence cases. Case 66 received only three days of initial AS treatment due to development
of neutropenia and completed anti-malarial therapy with an alternative short-acting drug. All remaining cases completed seven days of AS
monotherapy. Gametocytes were seen by microscopy for cases 33 (Day 0-21), 80 (Days 35 and 42), and 147 (Days 21 and 42). Case 88 had two
shared alleles on Df plus additional msp1 and msp2 loci. Case 140 had one new allele of msp2 detected on Days 3 and 5 but not on Day 0 or Df.
One shared msp1 allele detected at Df plus 1 new allele of glurp. (B) New infection. Case 112 new alleles of msp1, msp2 and glurp detected on Df
in addition to Plasmodium vivax.
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the parasites responsible for slow parasite clearance and
recurrent malaria are the dominant or co-dominant
clones in an acute infection. Further, because they are
also present in fast parasite clearers, they are well estab-
lished in the Tasanh parasite population. These data also
support recent reports of highly conserved, yet genotypi-
cally very distinct, populations of parasites from a num-
ber of sites in Cambodia including this study site [4].
In this setting of low malaria transmission and emer-
ging drug resistance, considerable heterogeneity within
the P. falciparum parasites was revealed in baseline sam-
ples from the symptomatic patient population. In keep-
ing with surveys from West Africa and Thailand, these
Cambodian isolates showed greater polymorphism of the
msp2 allelic family (IC3D7 and FC27) compared to msp1
and glurp [12,16]. These results showing the distribution
and diversity of msp1, msp2 and glurp in a relatively iso-
lated area of Western Cambodia are similar to those
from directly across the border in Trat Province,
Thailand [12]. Comparative data from other locations in
Cambodia is currently lacking.
Evidence of polyclonal infection, in the form of the
presence of two or more alleles from msp1, msp2 and
glurp within a single sample, was found in just 31% of
subjects overall at baseline (17, 26 and 8% for msp1,
msp2 and glurp, respectively). This suggests a relatively
low diversity of the P. falciparum parasite population in
this localized area of Western Cambodia. A study from
Kampala, Uganda, also a relatively low transmission
area, found 45/98 (46%) samples were polyclonal for
msp2 at baseline [17], while in Kenya 60% of asymptom-
atic blood smear positive children in an area of moderate
transmission in Kenya had two or more msp2 clones de-
tected [18]. For msp1 32% of 45 symptomatic and 64%
of 45 asymptomatic infections in a hyperendemic region
of Gabon had polyclonality of msp1 [19]. An intriguing
finding in this Cambodian study was that patients who
subsequently developed recurrent disease were signifi-
cantly more likely to harbour two or more clones at
baseline compared with the rest of the study population.
Since this is a location in which slow parasite clearanceduring AS treatment is the norm rather than the excep-
tion, the majority of slow clearers also had monoclonal
infections; this raises a question as to whether, in
addition to simply defining resistance as a certain pro-
portion of cases with prolonged parasite clearance time
or half-life, we should be broadening current research
objectives to include identification and follow-up of re-
current polyclonal infections so as to define their role as
potential agents of emerging resistance.
In the present study, six clones were demonstrated in
one baseline sample, although only two or three clones
were detected in the remaining 44 patients with polyclonal
infections. In general, studies from high transmission areas
have shown that asymptomatic malaria patients harbour
more parasite clones than those with symptomatic disease
[20]. The same is true for asymptomatic versus severe
malaria: in a post-mortem study from Malawi, tissue geno-
typing for sequestered parasites demonstrated that chil-
dren with cerebral malaria had sequestered parasite
populations less genetically complex than both their circu-
lating parasites and the circulating parasites in an asymp-
tomatic malaria group, despite the much higher parasite
burden [21]. The more homogeneous distribution of geno-
types in cerebral malaria than in asymptomatic cases sug-
gested the emergence of a single or small number of more
dominant parasite clones, although the authors did ac-
knowledge that the sheer burden of parasites in cases of
cerebral malaria may have prevented lesser populations
from being detected by PCR. Likewise, in this present
study, conducted in a localized low transmission setting in
Western Cambodia, cases of symptomatic disease, includ-
ing most cases with very prolonged parasite clearance,
tended to be dominated by single parasite clones. How-
ever, while there appeared to be an association of RO33
with some AS sensitive cases, no haplotype could be iden-
tified to be indicative of a resistant phenotype. Newer
techniques, such as the heteroduplex tracking assay
[22,23], may yield greater discrimination of clonal popula-
tions and identify haplotypes other than those used in this
present analysis.
Additional daily samples were genotyped during seven
days of AS treatment (Days 0 to 6) as well as on the day
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curred between 21 and 58 days after commencing AS.
Genotyping patterns from seven of nine treatment fail-
ure cases showed multiple parasite alleles of msp1 and/
or msp2 at baseline, although only a minority were then
detected during the following days of AS treatment. This
may be due to greater sensitivity of some parasite strains
to AS treatment, as well as to declining parasitaemia in
the small volume of sampled blood, or to a combination
of both. An alternative explanation for the disappearance
of some parasite strains, which later re-appear at the
time of treatment failure, is parasite dormancy triggered
by the presence of AS [24,25].
However, repeated genotyping of symptomatic travel-
lers returning from Africa before and during 96 hours of
quinine treatment for P. falciparum malaria in France
revealed 19/20 (95%) cases harboured between two and
five clones, with some cases having up to three domin-
ant clones in addition to other minority clones [26].
Moreover, quantification of clones revealed that while
the parasitaemia of some declined steadily during drug
treatment, others showed major fluctuations of parasit-
aemia that were apparently unrelated to the presence of
drug. Thus, a single baseline blood sample may provide
incomplete information on the diversity of parasite pop-
ulations present within a given patient. In contrast,
Färnert and colleagues found only one of 13 patients
with symptomatic malaria had new clones detected spor-
adically during 12-hourly sampling over a three to nine-
day period, despite more than half (seven of 13) having
multiple clones of msp1 and msp2 detected at baseline
[27]. This latter study reflects the findings in this study
in which just one of nine treatment failures and none of
14 slow parasite clearers had new alleles detected during
treatment.
A striking feature in patients undergoing longitudinal
sampling over seven days was the presence of parasite
DNA up to seven days after the initiation of AS therapy;
this may represent relatively drug-resistant P. falciparum
populations undergoing selection or modification in the
presence of drug. Parasite DNA is detectable in periph-
eral blood for less than 48 hours following the death of a
parasite in response to drug or immune mechanisms
and before being removed from the circulation by circu-
lating phagocytes and spleen macrophages [28]. There-
fore the presence of parasite DNA in blood beyond the
microscopy-calculated parasite clearance time does likely
represent the persistence of viable parasites. As well as
the increased sensitivity of PCR compared to microscopy
(in general 0.1 versus 10 parasites/μL [29]), an additional
explanation for the persistently positive PCR results
up to the final day of AS treatment is the presence of
gametocytes in the blood samples. However, in this
study only one of 23 patients in the AS-resistant grouphad gametocytes detected by microscopy during the first
seven days, and just one of nine LTF cases had gameto-
cytes on Df. Therefore the quantification results are un-
likely to be influenced significantly by the presence of
circulating gametocytes. Using current PCR strategies,
gametocytes can only be detected differentially by
reverse transcription-PCR (RT-PCR) [30]. The ability to
differentiate gametocytes from asexual parasites would
enable a more reliable estimate of true failure rates and
thus support efforts to limit the spread of drug resist-
ance and meet containment and elimination targets.
In this study, conventional genotyping assigned the
outcome of six of nine samples as recrudescence; add-
itional genotyping on Days 1-6 did not alter this assess-
ment. In two further cases, while the final classification
was not altered by additional genotyping the presence of
additional bands does illustrate some of the dilemmas
inherent in this genotyping technique. Mixed genotype
results may profoundly impact estimates of drug resist-
ance if they form a significant proportion of treatment
failure cases in clinical trials, and depending on how
they are interpreted [8]. If circulating strains at low para-
site densities are not detected in baseline samples be-
cause other (dominant) parasite strain(s) are present in
much larger quantities, they could still emerge later to
cause treatment failure, leading to the misclassification
of a recrudescence as a new infection and underestimat-
ing the amount of drug resistance in the patient popula-
tion [30]. The argument for analysing genotypes from
Day 1 as well as Day 0 samples for comparison with Df
has been made previously and may be particularly valuable
in high transmission settings [17,31]. Conversely, due to
incomplete immunity resulting from a single treated mal-
aria infection, patients could naturally re-acquire malaria
caused by the same parasite genotype if they return to an
endemic area with relatively little parasite genetic diversity,
this time leading to an over-estimate of drug resistance.
Current classification schemes of alleles for use in assign-
ing treatment outcome are limited and often subjective
and varying between observers. A recent MMV/WHO
consensus report on P. falciparum genotyping recom-
mends possible use of polyacrylamide gels, capillary elec-
trophoresis, or use of dedicated fragment sizing software
(used here), to increase discriminatory power and reduce
inconsistencies between clinical trial methodologies [8].
There are several limitations to this analysis. More
cases of treatment failure, in particular of new infections
with P. falciparum would have enabled potential mis-
classification of outcome to be examined in more detail.
Additional emergent minority populations may have
been detected if sampling had occurred more frequently
than once daily. Band size estimates, while measured by
automated reader with as much precision as possible,
may also have led to minor inaccuracies. Moreover band
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occur, leading to false categorization as different alleles.
Analysis of samples in this study was limited to once per
day so minority parasite clones with only a sporadic and
low-level presence in the peripheral circulation com-
pared to the dominant clone(s) could have been missed.
Conclusion
Limited genotyping of msp1, msp2 and glurp in malaria
patients from a localized area of Western Cambodia re-
vealed considerable variation in msp2 alleles but well-
conserved msp1 and glurp. Longitudinal genotyping
of cases with recurrent malaria during seven days of
anti-malarial treatment showed homogeneous genotype
dynamics and did not alter the outcome classification
compared to conventional genotyping at baseline and Df;
however it did serve to illustrate some of the inherent
complexities when interpreting the parasitological basis
of recurrent disease. In contrast to Africa, where malaria
transmission rates are higher and artemisinin resistance
does not currently appear problematic, lower polyclonal-
ity of infection was observed in malaria patients in
Cambodia. The exception was the group of recurrent
malaria infections in which polyclonality was much
higher. The potential role of polyclonal infections in
contributing to the spread of artemisinin resistance de-
serves further investigation.
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